Intrathecal 6-hydroxydopamine or cervical spinal hemisection reduces norepinephrine content, but not the density of alpha 2-adrenoceptors, in the cat lumbar spinal enlargement.
The effect of the intrathecal administration of the catecholaminergic neurotoxin 6-hydroxydopamine, or of hemisection of the spinal cord at the Cl level, on the density of alpha 2-adrenoceptors and on the norepinephrine, dopamine, and serotonin content in the cat lumbar spinal enlargement was determined 2, 7 or 21 days after performance of each type of lesion. The intrathecal administration of 6-hydroxydopamine produced a time-dependent reduction of norepinephrine content in the cat lumbar spinal enlargement (95% reduction at 21 days) without significantly altering the serotonin content in this same tissue of the same cats. The dopamine content of the dorsal horn was not changed significantly, whereas ventral horn dopamine content was depleted after intrathecal 6-hydroxydopamine. alpha 2-Adrenoceptor binding site density was not significantly different from control either 2 or 21 days after 6-hydroxydopamine, but was increased significantly (50%) over the control density 7 days after 6-hydroxydopamine. Hemisection of the cervical spinal cord produced a bilateral 40-60% reduction of norepinephrine content in both the dorsal and ventral horns of the cat lumbar spinal enlargement 7 and 21 days later. Cervical hemisection did not significantly alter the alpha 2-adrenoceptor binding site density in these same cats either 2, 7, or 21 days after performance of the lesion. It is concluded that alpha 2-adrenoceptors located on the terminals of descending noradrenergic or other spinopetal fibers do not represent a significant fraction of the total population of alpha 2-adrenoceptors present in the dorsal or ventral cat lumbar enlargement.
D000320:Adrenergic Fibers / Q000032:analysis; D000818:Animals; D002415:Cats; D004298:Dopamine / Q000032:analysis; D005260:Female; D006892:Hydroxydopamines / Q000494:pharmacology*; D007278:Injections, Spinal; D008297:Male; D009638:Norepinephrine / Q000032:analysis*; D016627:Oxidopamine; D011869:Radioligand Assay; D011942:Receptors, Adrenergic, alpha / Q000032:analysis*; D012701:Serotonin / Q000032:analysis; D013116:Spinal Cord / Q000032:analysis*; D013119:Spinal Cord Injuries / Q000378:metabolism*
D006892:Hydroxydopamines; D011942:Receptors, Adrenergic, alpha; D012701:Serotonin; D016627:Oxidopamine; D004298:Dopamine; D009638:Norepinephrine